The recent identification of USP28 loss in a significant number of p53-proficient tumors that exhibit p53-deficient transcriptional signatures suggests that the MSP may be selected against in a subset of cancers (Fito-Lopez et al., 2023). This evidence concerns the gene TP53 and cancer.